People · Operator
Named in public records as an officer, director or promoter · active 2020–2025 · Biotechnology, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Bugworks Research, Inc. | — | Biotechnology | Series B | $39.1M | $56.3M | 2020 |
| Violet Therapeutics, Inc. | — | Pharma | Series A | $7.4M | $65.7M | 2023 |
| Pahr Therapeutics, Inc. | — | Biotechnology | Series A | $4.7M | $17.8M | 2025 |
Atsushi Usami at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Atsushi Usami on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| ANDREW LEVIN | 1 | 17 |
| Meredith Fisher | 1 | 6 |
| Jonathan Behr | 1 | 4 |
| Neil Buckley | 1 | 3 |
| Ken Horne | 1 | 2 |
| William E Yelle | 1 | 2 |
| Pradeep Fernandes | 1 | 2 |
| Venkataraman Subramanian | 1 | 1 |
| Bala Subramanian | 1 | 1 |
| Atushi Usami | 1 | 1 |
| Tejasvi Ravi | 1 | 1 |
| Amanda Creedon | 1 | 1 |
| Santanu Datta | 1 | 1 |
| Anand Anandkumar | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.